These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 24376723)

  • 1. Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).
    de Biase D; Visani M; Malapelle U; Simonato F; Cesari V; Bellevicine C; Pession A; Troncone G; Fassina A; Tallini G
    PLoS One; 2013; 8(12):e83607. PubMed ID: 24376723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
    Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable
    Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
    Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
    Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective assessment of egfr mutation status in bronchoalveolar lavage and pleural fluids by next-generation sequencing.
    Buttitta F; Felicioni L; Del Grammastro M; Filice G; Di Lorito A; Malatesta S; Viola P; Centi I; D'Antuono T; Zappacosta R; Rosini S; Cuccurullo F; Marchetti A
    Clin Cancer Res; 2013 Feb; 19(3):691-8. PubMed ID: 23243218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
    Marchetti A; Del Grammastro M; Felicioni L; Malatesta S; Filice G; Centi I; De Pas T; Santoro A; Chella A; Brandes AA; Venturino P; Cuccurullo F; Crinò L; Buttitta F
    PLoS One; 2014; 9(8):e103883. PubMed ID: 25137181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection and characterization of classical and "uncommon" exon 19 Epidermal Growth Factor Receptor mutations in lung cancer by pyrosequencing.
    Righi L; Cuccurullo A; Vatrano S; Cappia S; Giachino D; De Giuli P; Ardine M; Novello S; Volante M; Scagliotti GV; Papotti M
    BMC Cancer; 2013 Mar; 13():114. PubMed ID: 23497146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer.
    Lechner A; Rai A; Rojas-Rudilla V; Kuang Y; Paweletz CP; Sholl LM; Dong F
    Arch Pathol Lab Med; 2024 May; 148(5):553-558. PubMed ID: 37639432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of ARMS and mutation specific IHC for common activating EGFR mutations analysis in small biopsy and cytology specimens of advanced non small cell lung cancer.
    Wang X; Wang G; Hao Y; Xu Y; Zhang L
    Int J Clin Exp Pathol; 2014; 7(7):4310-6. PubMed ID: 25120814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations.
    Vliegen L; Dooms C; De Kelver W; Verbeken E; Vansteenkiste J; Vandenberghe P
    Diagn Pathol; 2015 May; 10():57. PubMed ID: 26022577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.
    Kanaji N; Bandoh S; Ishii T; Kushida Y; Haba R; Kohno K; Dobashi H; Ohnishi H; Matsunaga T
    Mol Diagn Ther; 2011 Dec; 15(6):353-9. PubMed ID: 22117119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance evaluation of the Idylla™ EGFR Mutation Test on formalin-fixed paraffin-embedded tissue of non-small cell lung cancer.
    Delgado-García M; Weynand B; Gómez-Izquierdo L; Hernández MJ; Blanco ÁM; Varela M; Matias-Guiu X; Nadal E; Márquez-Lobo B; Alarcão A; de Álava E; Biscuola M
    BMC Cancer; 2020 Apr; 20(1):275. PubMed ID: 32245434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current methods to detect EGFR gene mutations as predictive factor for targeted therapies in non-small cell lung cancer - is there a "golden standard" in diagnostics?].
    Skroński M; Szpechciński A; Chorostowska-Wynimko J
    Pneumonol Alergol Pol; 2014; 82(3):311-22. PubMed ID: 24793156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
    Tsai TH; Su KY; Wu SG; Chang YL; Luo SC; Jan IS; Yu CJ; Yu SL; Shih JY; Yang PC
    Eur Respir J; 2012 Mar; 39(3):677-84. PubMed ID: 21719485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR Mutational Profiling in Non-Small Cell Lung Cancer: The Clinical Performance of a Sensitive Reverse-Hybridization Assay.
    Kriegshäuser G; Enko D; Novy M; Reitmayr A; Loidl A; Halwachs-Baumann G; Oberkanins C
    Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):388-392. PubMed ID: 27801728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.